Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aethlon Medical Inc AEMD

Technology Scientific & Technical Instruments
Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.


NDAQ:AEMD - Post by User

Aethlon Medical Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(687)
•••
  • mercedesmanX
Post by mercedesmanon Sep 14, 2021 2:48pm
188 Views
Post# 33855960

Starting to add again.

Starting to add again.Especially since they are now loaded up with cash (about $ 1.67 in cash, per share o/s...low float)

News of a CRO on their 40 person Covid Study soon. Maybe a few anecdotal stories to go along with it?

Last raise was at $ 9 (which brought in $ 17M) .  Being a value investor, I will add at prices  between $ 2.50 and $ 3.50.

The story sells.  Removing deadly viruses from blood (including Covid) via filtration.


Who knows when the next spike will happen ?



MM
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities